Critical Care Nursing Clinics of North America

Crit Care Nurs Clin N Am 14 (2002) 435–453

Index

Note: Page numbers of article titles are in **boldface** type.

A

Abciximab, in anticoagulation, 12

Absorption, drug, in elderly, 111–112
  in renal failure, 77, 79

Access, in multisite advanced practice nursing, resources for, 303

Accountability, of patient, as partner in health care, 399
  shared, for patient safety, 355

Accreditation organizations, outcome selection from, for advanced practice nursing research, 256–257

Acebutolol, adverse effects of, 60
  indications and action of, 59–60

Active listening, in end of life care, 134

Acute care. See also *Pediatric acute care.*
  collaborative practice in, **305–311**
  nurse anesthetist–physician, 306–307
  nurse practitioner–physician, 309
  pediatric nurse specialist–physician, 308–309
  specialty nurse practitioner–physician, 309–310

Acute care nurse practitioner (ACNP), 316
  collaboration with physician, 309–310

Acute myocardial infarction (AMI), in diabetes mellitus, insulin-glucose therapy in, 95–96

Adenosine, adverse effects of, 64
  indication and action of, 65

Administration, support of, in multisite advanced practice nursing, 300–301
  validation of advanced practice nursing role to, credentialing process in, 276–277
  definition of need for, 275
  keys to success in, 279
  performance criteria to document practice parameters, 276
  utilizing outcome data in, for cost effectiveness, 277
  for patient/family/physician satisfaction, 279
  for quality of care, 277–278
  other outcomes in, 279

Advance directives, and withdrawal of life support, 187–189
  and withdrawal of nutritional support, 194
  completion of, barriers to, 215–216
  rates of, 215
  patient and community education in, **215–217**
  physician culture and, 215–216
  race and, 215

Advanced practice nurse, as case manager, of aging patient, 285–288
  as entrepreneur, 223
  as intrapreneur, 223
  as outcomes manager, for long-term mechanically ventilated patient, 236–240
  in pediatric acute care. See under *Pediatric acute care.*

Advanced practice nursing, and outcomes for mechanically ventilated medical ICU patients, **231–243**
  characteristics for, 223–224
  clinical practice opportunities in, **223–239**
  for aging patient, case management in, **281–291**. See also under *Aging patient.*
  future of, characteristics in, 321 role in, 321
  in acute care, collaborative practice in, **305–311**
  in pediatric acute care, **313–324**
  multisite, administrative support for, 300–301
  culture and politics in, 302–303
  definition of, 299
  documentation in, 304
  essential elements of, 300–304
  examples of, 299–300
  integration across sites and, 303–304
  key relationships in, 301–302

0899-5885/02/$ – see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0899-5885(02)00074-6

learning and, 300
organizational skills in, 303
personal outcomes in, 304
resources in, 303
responsibilities in, **299–304**
self-evaluation for, 300
spheres of influence and, 300
outcomes research on, **245–251**
conduct of, **261–268**
currently available, **269–274**
designs for, **293–298**
for role validation, **275–270**
outcome for, **253–260**
practice models in. See under *Practice models.*
practice opportunities in, attributes for
providers in, 226
billing in, 226
challenges and rewards in, 226–227
criteria for success of, 226–227
lifestyle considerations for, 226–227
nurse benefits in, 227
physician benefits in, 226–227
roles and responsibilities in, 226
specialty roles in, 313

Advocacy, in critical care nursing practice, 139–140

Afterload, drugs affecting, 74–75

Age, in outcomes research, controlling for, 264

Aging, demographics of, 281
medication administration safety in. See under *Elderly.*
popular theories of, stress, 283
wear and tear, 282–283
theoretic perspectives on, 281–282
cross-link theory, 282
damage theory, 282
free radical theory, 282
immunologic theory, 282

Aging patient, adaptation and health and, response shift as adaptation, 283
advanced practice nursing case management of, **281–291**
differentiation from care management, 287
in atypical case study, 285–286, 288–289
patient candidates for, 287–288
risk recognition in, 287–288
selected principles of, 286–287
vs. baccalaureate-prepared case manager for, 287
definition of, 284
frailty of, 283–284
and physical functioning of, 283–284
measurement of health in, via progress or decline, 283–284
physical functioning as component of health-related quality of life, 284–285

Alcohol use, in elderly patient, assessment of, 431–432

Alteplase (t-PA), for acute myocardial infarction, in elderly, 118

Amiodarone, adverse effects of, 61
indications and action of, 62
metabolism of, in elderly, 114

Amrinone, to increase contractility, 74, 76

Angiotensin-converting enzyme (ACE) inhibitors, in renal failure, 80

Antacids, aluminum-containing, drug inhibition by, in elderly, 117
for stress ulcers, 45–46

Antibiotics, for gram-positive infections, 21–28. *See also under Gram-positive infections.*
for future use, 27–28
in current use, 27
resistance to, mechanisms of, 19–21

Anticoagulant(s), heparin, unfractionated and low-molecular-weight, 13–14
history of, 7–8
warfarin, 12–13

Anticoagulation, during extracorporeal therapies, 14–15

Antidysrhythmic agents, class IA, 54–58
class IB, 58–59
class IC, 58–59, 63–65
class II β-blockers, 59–60
electrophysiology and, principles of, 53–54
for atrial fibrillation, 66
limitations of, 67
for conversion, 66–67
for maintenance of sinus rhythm, 67
for rate control, 66
in children, 67–68
in elderly, 67
in heart failure, 68
in special populations, 66
miscellaneous, adenosine, 65
digoxin, 65
overview of, **53–69**
pharmacodynamics and, 54

Antiplatelet drugs, 10–11

Antithymocyte globulin, for immunosuppression, in kidney transplantation, 106–107

Argatroban, in anticoagulation, 14

Aspirin, as antiplatelet agent, 10–11
history of, 7

Assisted suicide, 148

Atrial fibrillation, pharmacotherapy for, 66
limitations of, 67

Automaticity, cardiac, 72

Autonomy, and withdrawal of nutritional support, 194
in end of life care, 144
pain management and, 166–168
respect for, and error reporting and disclosure, 403

Azathioprine, for immunosuppression, 99, 102–103

B

Basiliximab, for immunosuppression, 107

Beneficence, and error reporting and disclosure, 403
and withdrawal of nutritional support, 194
in end of life care, 145
pain management and, 166–167
in ICU care, 159

Benzodiazepines, in elderly patient, withdrawal from, 432

Best interest standard, surrogate decision making and, 144

Beta-lactam antibiotic(s), carbapenems, 22–23
cephalosporins, 22–23
penicillins, 21–22

Bicarbonate, in diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome, 92–93

Billing, in collaborative practice, 226

Blood–surface interactions. See also *Anticoagulant(s); Coagulation.*
drugs limiting, **7–16**
research and development in, 15

Bretylium, adverse effects of, 61
indications and action of, 63

Bumetanide, in preload, 74

C

Calcium antagonists, nondihydropyridine, in renal failure, 80

Calcium channel blockers, for vasodilation, 74

Carbamazepine, parenteral formulation of, 33

Carbapenems, for gram-positive infections, 22–23

Cardiac catheterization, in infants and children, inhaled nitric oxide in, 2–3

Cardiovascular system, in elderly, medication administration safety and, 429–430

Cardioversion, pharmacotherapy for, 66–67

Care, as moral thinking, 404

Care management, case management *vs.*, 287

Case management, advanced practice nurse in, patient candidate for, 287–288
principles in, 286–287
risk recognition in, 287–288
vs. care management, 287
of aging patient, case study of, 285–286, 288–289
vs. care management, 287

Central venous catheter, bloodstream infection from, 420–421
insertion of, barrier precautions in, 421

Cephalosporins, for gram-positive infections, 22–23

Cerebral edema, in diabetic ketoacidosis, 93–94

Children, antidysrhythmic pharmacotherapy in, 67–68

Clindamycin, for gram-positive infections, 22–23

Clinical nurse specialist (CNS), in neonatal ICU, 224
in pediatric acute care, 313–315

Clinical nurse specialist–physician collaboration, 307–308

Clinical pathway, multidisciplinary, for mechanical ventilation outcomes program, 233–236

Clinical practice guidelines, assessment of, 349–350

Clopidogrel, as platelet receptor antagonist, 11

Coagulation, aspirin in, 10–11
cofactors to, 8
glucoprotein IIb/IIIb receptor antagonists in, 12
NSAIDS in, 11
pathways in, common, 8–10
extrinsic, 8–9
intrinsic, 9–10

platelets in, 10
prevention of, anticoagulants in, 12–15
antiplatelet drugs in, 10–11
thienopyridines in, 11–12

Collaborative practice, collaboration and, characteristics of, 305–306
definition of, 306
in acute care, **305–311**
in advanced practice nursing, 306–307
clinical nurse specialist–physician, 307–308
definitions in, 305–306
nurse anesthetist–physician, 306–307
nurse practitioner–physician, 309
pediatric nurse specialist–physician, 308–309
specialty nurse practitioner–physician, 309–310

Comfort care, at end of life, 166, 168

Communication, and bedside fraud, in intensive care unit, 162
in end of life care, 197
patient values and, 149
in multisite advanced practice nursing, resources for, 303
in palliative care, of children, 210
in withdrawal of life support, family needs and, 188–190
in withdrawal of nutritional support, 195
moral distress and, 176

Community, in palliative care, of children, 212

Community education, in advance directives, **215–217**

Competency, in end of life decision making, 144

Confusional states, drug-induced, in elderly, 116

Consent, in end of life decision making, 144

Continuity, in multisite advanced practice nursing, resources for, 303

Continuous aspiration of subglottic secretions, in prevention of nosocomial pneumonia, 420

Contractility, cardiac, 72–73
drugs affecting, 75–76

Contributory cause analysis, of errors, 355–356

Control charts, in error reporting, 381–382

Coronary heart disease, in elderly, medication administration safety and, 429–430

Corticosteroids, for immunosuppression, 102

Cost effectiveness, of advanced practice nursing, 277

Creatine, serum, in diabetes mellitus, 90

Credentialing, for advanced practice nursing, 276–277

Critical thinking, attributes of, 388–389
development of, failure mode and effects analysis in, 387
human factor science in, 385
increasing of, and error reduction, **385–390**
in safety culture development, 388–389
thought processes in, stages in, 386

Culture, advance directives and, 215
in end of life care, 149
in multisite advanced practice nursing, 302–303
of critical care, 135
organizational, patient safety and, 342–343
teamwork and, 336

Cyclosporine, for immunosuppression, 99, 103–104, 107

D

Daclizumab, for immunosuppression, in kidney transplantation, 107

Dalfopristin, for gram-positive infections, 23–24

Dana-Farber Cancer Institute, medication error incidents in, historical, 359–360

Death, nurses' personal relationship with, 139–140
of children, case example of, 207
significance of, 207–208
peaceful, promotion of, **201–206**

Death with dignity, legal and ethical challenges to, 141

Decision making. See also *Surrogate decision making.*
in end of life care, 187–188
ethical, 144–145
patient values and preferences and, 135
physician *vs.* patient in, 202–203
surrogate, 144

Decision-making, by patient, as partner in health care, 399
critical thinking process in, 386
evidence-based, in error prevention, 349
team input in, for patient safety, 344

Dehydration, in end of life care, benefits of, 145–146, 195

Depression, in elderly, mirtazapine for, 116

Design, for outcomes research, examples of, 294–297
in advanced practice nursing, 246, 248
selection of, 293–294, 296–297

Diabetes mellitus, as major health problem, 81–82
complications of. See also *specific, e.g. Diabetic ketoacidosis (DKA).*
acute, 83
cerebral edema, 93–94
diabetic ketoacidosis, 83–86
hyperglycemic hyperosmolar nonketotic syndrome, 86–87
hypoglycemia, 87–88
laboratory values in, 89–91
metabolic, 93
precipitating factors in, 88
signs and symptoms of, 88–89
treatment of, 91–93
costs of, 81–82
in cardiac patients, pharmacotherapy for, 95–96
latent autoimmune diabetes in adults, 82
transition from critical care unit and, 94–95
type 1, description of, 82
type 2, insulin resistance in, 82–83
insulin secretion in, reduction of, 83

Diabetic ketoacidosis (DKA), complications of,
cerebral edema, 93–94
counter-regulatory hormones in, 85–86
metabolic, 93
description of, 83
insulin deficiency in, 83–84
carbohydrate metabolism and, 84
fat metabolism and, 84–85
protein metabolism and, 85–86
laboratory values in, 89–91
precipitating factors in, 88
treatment of, bicarbonate in, 92–93
electrolytes in, 92
fluids in, 92
general measure in, 91
insulin in, 91–92

Diagnosis-related groups (DRGs), in outcomes research, controlling for, 264

Diazepam, rectal formulation of, 33

Digestive tract decontamination, in prevention of nosocomial pneumonia, 420

Digoxin, adverse effects of, 64
indication and action of, 65
to increase contractility, 75–76
toxicity of, in elderly, 115

Diltiazem, adverse effects of, 64
indications and action of, 64

Disopyramide, indications and action of, 55, 58

Diuretics, for high afterload, 75
in preload states, 74

Dobutamine, to increase contractility, 76

Documentation, in multisite advanced practice nursing, 304

Dofetilide, adverse effects of, 61
indications and action of, 63

Do not resuscitate (DNR) order, in ICU, 161
physician and family *vs.* patient and, 203

Dopamine, for decreased afterload, 75

Double effect rule, in pain management, 146

Duty-based (deontologic) ethics, error reporting and disclosure in, 404

E

Education, for patient safety, 344–345
in advance directives, for health care personnel, 216–217
for patients and community, 216
in end of life care, 150
clinicians, 198–199
physicians, 217
of clinical staff, for pediatric palliative care, 211
withdrawal of nutritional support and, 195

Eighty/twenty (80/20) rule. See also under *High-alert medication.*
history of, 369

Elderly, antidysrhythmic pharmacotherapy for, 67
medication administration safety in, **427–434**
medication review and, 431–432
medications of concern and, 432
pathophysiologic changes and, 427–431
cardiovascular, 429–430
endocrine and immune systems, 431
gastrointestinal, 430–431
integumentary, 428
neurologic, 428
pulmonary, 430
renal, 421
sensory, 428–429
practical suggestions for, 433
medications in, **111–119**
absorption of, 111–112
alternative, 115
excretion of, 115

for pain, 117–118
hepatic metabolism and, 113–115
protein-binding of, 113
unintended effects of, 115–117
with short half-lives, 118
pathophysiologic changes in, general, 427
hepatic, 427
physiologic changes in, patient monitoring and, 112–113
pharmacodynamics and, 111–113
pharmacokinetics and, 111–112

Electrolytes, in diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome, 92

Emergency Care Research Institute, Medical Devices Safety Reports of, 412–413
document types in, 413

Emergency Nurses Association, on family presence during resuscitation, 178–179, 183

Endocrine system, in elderly, medication administration safety and, 431

End of life care, alternatives and change in, Institute of Medicine study and, 142
Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatment study and, 142
autonomy in, 144, 166–168
barriers to ideal, 198–199
legal myths as, 143–144
benefits and burdens in, 135–136
clinical context of, influencing, 149–151
clinician education and training and, 198–199
communication in, values and, 149
critical care nursing and, 134–136
concerns in, 134
milieu and culture of critical care and, 135, 149
cultural and spiritual care in, 148–149
decision making in, nurses *vs.* physicians in, 129
educational resources for, 204–205
education for critical care, 150
ethical issues in, **141–155**
ethical perspectives in, 144–148
ethical violations in, response to, 168–169
ethics committees in, 150
financing of, 205
hospice and palliative care and, 142–143
hospital culture and, 198–199
ICU care and, **197–200**
ICU *vs.* palliative care goals and values in, 136
improvement of, strategies for, 148–149
Institute of Medicine on, 348–349
legal instruments and surrogate decision-making in, 144
legal issues in, **141–155**
legal perspectives in, consent, competency, decision making capacity, 143–144
medical *vs.* nursing model of, 135
moral uncertainty in, 136
Nursing Leadership Academy for, 133–134
optimal, 197–198
pain management in, 146, **165–170**
palliation *vs.* cure in, 148
physicians *vs.* nurses and, 217
policy and position statements of professional organizations and, 143
public knowledge and, 198–199
public policy and community dialogue and, 150–151
quality, domains of, 203
research for, 150
sociocultural context of, 141
spiritual care in, **171–176**
technological imperative and, 141–142
unification *vs.* fragmentation of, 199–200
value conflicts in, 135–136

Endotracheal tube, nosocomial pneumonia from, 420

Enteral nutrition, for stress ulcers, 48

Epinephrine, for decreased afterload, 75

Epitifibatide, in anticoagulation, 12

Equipment, standardization of, for patient safety, 344

Error. See also *Medication errors.*
analysis of, for contributory cause, 355–356
for root cause. See *Root cause analysis.*
definition of, 334
definitions of, 401
disclosure of, definition of, 401
in American Medical Association Code of Ethics, 402
failure mode and effects analysis of, 387
human factor in, 386–387
incidents of mal-outcome as, disclosure to patient, 402
in medical device use, knowledge-based, 408–409
latent, 409
rule-based, 408–409
skill-based, 408–409
JCAHCO definition of, 414
lapses and, 386
measurement and reporting of, analysis of findings in, 378

clinical value compass in, 376–377, 383
data analysis in, 378–380
data quality and, 379–380
statistical tests in, 379–380
database construction for, 377
measurement tools for, 380–382
outcomes in, 376–378
process in, 376–377
structured care methods in, design of, 378
implementation of, 378
structure in, 376–377
measurement of, fishbone diagram in, 380
serial V concept for, 377, 380–381
reporting and disclosing of, moral obligation in, **401–405**
reporting and disclosure of nursing errors, American Nurses' Association Code of Ethics and, 402
competing interests in, 402
concerns in, 402–405
ethical obligations in, 403
in duty-based (deontologic) ethics, 404
in ethics-of-care theory, 404
in utilitarian (consequentialist) ethics, 403–404
nurses' moral obligation in, 405
ramifications of, for nurses and nursing, 403
reasons for failure to, 403
reporting of, benchmarking and, 382
control charts in, 381–382
definition of, 401
format of, considerations in, 383–384
documentation in, 384
goal-directed action planning in, 383
risk and, 382
severity adjustment in, 382–383
types of, 386

Error prevention, proactive, contributory cause analysis, 355–356
evidence-based decision-making, 349
implementation of care guidelines in, 349–350
in intensive care unit, **347–358**
medication use system, evaluation of, 353–355
medication use system evaluation in, 353–355
multidisciplinary collaboration in, 349–351
national standards and, 347–348
nurse in, 350–351
observability for, 352
patient/family control in, 348–349
pharmacist in, 351
physician in, 350
process absorbers for, 352
redundancy in multi-step systems, 352
respiratory therapist in, 351
shared accountability in, 355
skill maintenance program for, 352–353
system variance in, weak human factors and, 351–353
visual control in, 355

Error rates, capturing and reporting, **375–384**

Error reduction, critical thinking in, **385–390**
multidisciplinary approach to, **359–367**
action plan in, 365
clinician cooperation/collaboration in, 360
executive leadership in, 361
expansion beyond patient care setting, 366–367
individual accountability *vs.* systems issues in, 361–362
Medication Event Subcommittee in, 360
nonpunitive environment in, 361
patient and family disclosure in, 363
patient and family involvement in, 363, 366
process design in, 361–363, 366
root cause analysis in, 360, 363–365
rounding in, 361

Esmolol, 60
adverse effects of, 60

Ethics, and withdrawal of nutritional support, 194
in critical care, 145–146
in end of life care, **141–155**
in ICU, **157–163**. See also under *Intensive care unit (ICU).*
in pain management, **165–170**
in reporting and disclosure of error, 402

Ethics committee, pain management and, in end of life care, 169

Ethics-of-care theory, commitment to relationship in, 404–405
error reporting and disclosure in, 404

Euthanasia, 148
definition of, 148

F

Failure mode and effects analysis (FMEA), as team exercise, in critical thinking, 387
in error identification, 387

Family, error disclosure to, 363
in error reduction, 363–366

needs of, during withdrawal of life support, **187–191**. See also *Withdrawal of life support.*
end of life spiritual care and, 173–174
of dying patient, 204
resuscitation and, presence during, **177–185**. See also under *Resuscitation.*

Fecal impaction, in elderly, medication-induced, 430–431

Federal government initiatives, outcome selection from, for advanced practice nursing research, 253–257

Fenoldopam, for decreased afterload, 75

Flecainide, indications and action of, 59

Fluids, in diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic ketoacidosis, 92

Fluoroquinolones, for gram-positive infections, 25–26

Fosphenytoin, for seizure control, in neuroscience intensive care unit, 31–33

Foundation for Accountability, outcome selection from, for advanced practice nursing research, 256–257

Frailty, characterization of, 283–284
of aging patients, autonomy criterion and, 284
standardized definition of, 284

Furosemide, in preload, 74

G

Gastrointestinal system, in elderly, oral medication administration safety and, 430

Gastrointestinal tract, upper, in nosocomial pneumonia, 420

Gender, in outcomes research, controlling for, 264

Glucagon, in diabetic ketoacidosis, 85–86
effects of, 85–86

Glucoprotein IIb/IIIa receptor antagonists, in anticoagulation, 12

Glycopeptides, for gram-positive infections, 23–24

Gram-positive infections, aerobic and anaerobic bacteria in, 17–19
antibiotics for, β-lactams, 21–23
dosing of, 26–27
for future use, 27–28
glycopeptides, 23–24
in current use, 27
ketolides, 23–24
lincosamides, 23–24
oxazolidinones, 24–25
quinolones, 25–26
rifamycin, 26

Group practice, in advanced practice nursing, challenges and rewards in, 227–228
criteria for success of, 228
ownership of, 227

H

Haloperidol, in neuroscience intensive care unit, 37

Handwashing, nosocomial infection and, prevention of, 418, 420–421

Hazardous condition, JCAHCO definition of, 414

Healing, *vs.* cure, in palliative care, 138

Health care, aviation model in, adaptation of, 334–335

Health care system, errors in, comparison with aviation industry, 334
factors in, 334
mortality and, 334

Healthy People 2010, outcome selection from, for advanced practice nursing research, 253–254

Hearing, in elderly, medication administration safety and, 429

Heart failure, antidysrhythmic pharmacotherapy for, 68

Hemodynamic parameters, arterial pressures, 71
assessment of, 71
circulatory system in, 71–72
pharmacologic interventions and, **71–76**

Hemodynamics, afterload in, 73
drugs affecting, 74–75
contractility in, 72–73
neurohormonal control of heart in, 73
pharmacologic intervention in, 73–76
preload in, 72–73
drugs affecting, 73–74

Heparin, history of, 7
unfractionated and low-molecular weight, 13–14

Herbal preparations, elderly use of, safety concerns and, 432

High-alert medications, 371–372
errors with, making visible, 371

minimizing consequences of, 371, 373
reduction or elimination of, 371
root causes analysis of, 374
Institute for Safe Medication Practices and, 374
patient safety and, 342
problems associated with, 372
80/20 rule and, **369–374**
safeguarding of, fail-safes in, 373
order communication in, standardization of
system redundancies in, 373
special considerations with, 371

High-risk drugs, ordering and administration of, patient safety and, 342

Histamine-2 receptor antagonists, for stress ulcers, 46–47

Homeostenosis, in aging population, 288

Home remedies, use by elderly, 115, 117

Hospice, barriers to, 142–143
palliative care and, 128

Hospital practice, in advanced practice nursing, Medicare billing in, 228
reporting structure in, 228

Human factor, in error, 386–387
in patient safety system evaluation, example of, 353–354

Human factor engineering, medical device errors and, 411

Human factor science, in critical thinking, 385, 390

Hyperglycemia. See also *Hyperglycemic hyperosmolar nonketotic syndrome (HHNS).*
in diabetes mellitus, 89

Hyperglycemic hyperosmolar nonketotic syndrome (HHNS), complications of, cerebral edema, 93–94
metabolic, 93
laboratory values in, 89–91
pathogenesis of, 86–87
pathophysiology of, 86–87
precipitating factors in, 88
signs and symptoms of, 88–89
treatment of, bicarbonate in, 92–93
electrolytes in, 92
fluids in, 92
insulin in, 91–92

Hyperventilation, for pulmonary hypertension in newborn, 2

Hypoglycemia, in diabetes mellitus, pathophysiology of, 87–88
precipitating factors in, 88
signs and symptoms of, 88–89
laboratory values in, 89–91

Hypoglycemic unawareness, definition of, 88

I

Ibultilide, adverse effects of, 61, 63
indications and action of, 63

Immune system, in elderly, medication administration safety and, 431

Immunosuppressive(s), in kidney transplantation, 99–101
azathioprine, 99, 102–103
corticosteroids, 102
current, 102–105
cyclosporine, 99, 104–105, 107
future, 107–108
history of, 99, 101
in induction therapy, 106–107
mycophenolate mofetil, 104–105
sirolimus, 105
tacrolimus, 104, 107

Induction therapy, in immunosuppression, antithymocyte globulin in, equine, 106
rabbit, 106–107
basilizimab for, 107
daclizumab for, 107
muromonab-CD3 for, 106

Inhaled nitric oxide, in infants and children, concentration of, 3
in cardiac catheterization, 2–3
in diagnosis, 2
toxic effects of, conversion to nitric dioxide, 4
methemoglobulin formation, 3–4
platelet function alteration, 4
weaning from, 4

Inotropic medications, for decreased contractility, 75

Institute for Safe Medication Practices (ISMP), information from, 374
Medication Safety Self-Assessment Survey of, 353, 356–357

Institute of Medicine (IOM), end of life care and, 142
on death trajectories, 203
on end of life care, patient and family in, 348–349
on patient safety, 366

on quality, 366
patient safety and, recommendations for, 348
quality of care and, 348
safety, requirements for, 356

Insulin, deficiency of, in diabetes mellitus, effects of, 83–85
in DKA and HHNS, 91–92
intravenous protocol for, 94
sliding scale therapy, in transition from critical care unit, 94–95
subcutaneous, algorithm for, 95

Integumentary system, in elderly, topical medication administration safety and, 428

Intensive care, decision making in, 157

Intensive care unit (ICU), end of life care and, training for, 157–158
end of life care on, case example of, 198
optimal, 197–198
reformation of, 199–200
ethical conflicts in, 158
ethical issues in, bedside rationing, 161
do not resuscitate and terminally ill issues, 161
generational, 159–160
high technology treatment *vs.* experimentation, 160–161
intergenerational, 160
restraint use, 161
surrogate decision making in, 161
ethical principles in, 158–159
ethics of care in, 158
neonatal, ethical issues in, 159–160
nurses in, 158
pediatric, ethical issues in, 160
power issues in, 158
refusal of treatment in, 162

J

Joint Commission on Accreditation of Health Care Organizations (JCAHCO), initiatives of, outcome for advanced practice nursing research and, 256
medical device error reporting and, definitions in, 414
on patient safety, 347
patient safety programs, component requirements of, 413

Justice, and error reporting and disclosure, 403
in end of life care, 145
in ICU care, 159

K

Ketolides, for gram-positive infections, 23–24

Kidney, in elderly, medication administration safety and, 431
transplantation of, immunosuppressives in, **99–109**

L

Lapses, information storage and, 386

Latent autoimmune diabetes in adults (LADA), 82

Leaders, formal and informal, in multisite advanced practice nursing, 301–302

Leadership, unit, advanced practice nurse integration into, 320

Leapfrog Group, patient safety standards and, 347–348

Learning, in multisite advanced practice nursing, 300

Legal issues, in end of life care, **141–155**. See also under *End of life care.*

Lepirudin, in anticoagulation, 14

Lidocaine, indications and action of, 58
metabolism of, in elderly, 114

Life support, withdrawal of, family needs during, **187–191**

Lincosamides, for gram-positive infections, 23–24

Linezolid, for gram-positive infections, 24–25

Liver function, in elderly, 114–115

Long-term ventilated patient project, advanced practice nurse as outcomes manager in, clinical pathway development for, multidisciplinary, 233–236
evaluation of Burns Weaning Assessment Program in, 242
extension to pulmonary suite, 241
future directions, 240–241
goals for outcomes manager, 236
impact of, 240–241
obstacles to, buy-in, 237–239
communication and adherence to weaning plan, 240
time management, unit leadership, 240
selection of outcomes manager for, 233
weaning protocol for, 232
weaning protocol for, 232

Loop diuretics, in elderly, confusion with, 115

M

Macrolides, for gram-positive infections, 23–24

Magnesium, for stress ulcers, 49

Mannitol, in preload, 74

Mechanical ventilation, nosocomial pneumonia from, 419–420
on medical ICU, advanced practice nurses' outcomes program for, **231–243**
background and rationale for, 231–232
compliance with, 232
for long-term mechanically ventilated patients, 233
multidisciplinary clinical pathway development for, 233–236
outcomes manager for, 233, 236–230
weaning protocol on, 232

Medicaid, research initiatives of, outcomes selection from, 254–255

Medical device error, **407–415**
assessment criteria for, human factors engineering, 411
interactive complexity and tight coupling, 411
linear and complex processes and systems, 411
cataloging of, as risk assessment function, 411
FDA and, adverse event and, definition of, 412
device failure reporting categories, 412
medical device database, 412
reporting system for, 412
information on, Emergency Care Research Institute, 412–413
from Emergency Care Research Institute, 412–413
from FDA, 412–413
medical device and, definition of, 407–408
medical technology and, definition of, 407
under-reporting of, technical issues in, 410

Medical devices, adverse events with, under-reporting of, 410
classification of, 510K exemption, 408
risk-level basis in, 408
failure of, assessment criteria for, 410–411
classification of, 409–410
failures of, classification of, 409–410
near accidents with, 409–410
and malfunctions, 409–410
reporting of, 409–410
problems frequently reported with, 414
use of, accidents in, 409
definitions of errors in, 408–409
errors in, 408–409
incidents in, 409
sources of errors with, 410–411

Medical futility, in end of life care, 147

Medicare, billing of, in advanced practice nursing hospital practice, 228
research initiatives of, outcomes selection from, 254–255

Medication errors. See also *Error.*
costs of, emotional and physical, 370
to hospital, 369–370
death and injuries from, 360
at Dana-Farber Cancer Institute, 359–360
defined, 417
error-prone processes and, 370
high-risk patient populations in, 370
reduction of, comparison with infection control, 417
scope of problem, 369–370

Medication review, in elderly patient, 431
at admission and discharge, 433

Medication Safety Self-Assessment Survey, 353, 356–357

Memory, in elderly, medication administration safety and, 428

Mentoring, in multisite advanced practice nursing, 304

Metabolic acidosis. See also *Diabetic ketoacidosis (DKA).*
in diabetes mellitus, 89–90

Mexiletin, indications and action of, 58

Midazolam, in neuroscience intensive care unit, 37

Mistakes, as lack of expertise and planning, 386
knowledge-based, 408–409

Moral distress, caregiver, in end of life care, 149
of critical care nurses, 175–176

Moral obligation, in reporting and disclosure of errors, **401–405**

Moral uncertainty, in end of life care, 136

Moricizine, indications and action of, 58

Mortality rates, teamwork and, 335

Motor dysfunction, in elderly, medication administration safety and, 428

Multi-drug resistant bacteria, in nosocomial infections, antibiotic strategies for, 418
multifactorial approaches to, 418–419

Muromonab-CD3, for immunosuppression, in kidney transplantation, 107

Mycophenolate mofetil, for immunosuppression, 104–105

N

National Committee for Quality Assurance, outcome selection from, for advanced practice nursing research, 256–257

National Quality Forum (NQF), evidence-based safe practices of, 375–376
National Quality Measurement and Reporting System, goals of, 376

Near accidents, definitions of, 409
device malfunctions and, 409
reporting of, ambiguity of, 410
in aviation and health care, 410
value of, 409–410

Near miss, JCAHCO definition of, 414

Neonatal intensive care unit, clinical nurse specialist and nurse practitioner in, 315
ethical issues in, 159–160

Nervous system, in elderly, medication administration safety and, 428

Neuromuscular blocking agents, metabolism of, in elderly, 114

Neuroscience intensive care unit (NICU), pharmacologic advances in, **31–38**
for clot lysis, 33–35
for sedation, 35–37
fr seizure control, 31–33

Neuro-surgical trauma intensive care unit (NTICU), at Memorial Hermann Hospital,
changes in, for patient safety, 344–345

Nitrendipine, for stress ulcers, 48

Nitroglycerin, for high preload, 74

Nitroprusside, for high preload, 74

Nitrous oxide, inhaled, in infants and children, **1–6**

Nonmaleficence, and withdrawal of nutritional support, 194
euthanasia and assisted suicide and, 148
in end of life care, 145
in ICU care, 159

Non-maleficence, and error reporting and disclosure, 403

Nonsteroidal anti-inflammatory drugs (NSAIDS), as antiplatelet agents, 11
elderly use of, safety concerns and, 432

Norepinephrine, for decreased afterload, 75

Nosocomial infection(s), **417–425**
bloodstream, antimicrobial catheters and, 421
central venous catheter-associated, 420–421
intravascular device-associated, 420–421
risk reduction strategies for, 421–422
definition of, 417
hand hygiene and, 418, 420–421
pneumonia, gastrointestinal tract in, 420
risk for, 419–420
ventilator-associated, 419–420
sites of, 417
staffing and, 418
unit level interventions and, 418–419
urinary tract, causes of, 419
risk and reduction strategies for, 419

Nurse, in error prevention, 350–351

Nurse anesthetists–physician collaboration, 306–307

Nurse practitioner (NP). See also *Pediatric nurse practitioner (PNP).*
collaboration with physician, 309
in neonatal ICU, 316
in pediatric acute care, 313–314

Nursing Leadership Academy for End-of-Life Care, 133–134, 140

Nursing shortage, and end of life care, 150–151

Nutritional support, withdrawal of, **193–196**

O

Omeprazole, for stress ulcers, 48

Orders, communication standardization of, for error prevention, 373

Organization, in multisite advanced practice nursing, 303

Osmolality, of antibiotics, in gram-negative infections, 26–27
of propofol, 35–36
in renal failure, 78
serum, in diabetes mellitus, 90

Outcomes, definition of, 376
domains of, 376–377
for outcomes research in advanced practice

nursing, accreditation organization initiatives, Health Plan Employer Data and Information Set and, 257
Joint Commission on Accreditation of Healthcare Organizations, 256
National Committee for Quality Assurance, 256–257
accreditation organizations and quality indicators, 256–257
federal government initiatives, 253–257
Centers for Medicare and Medicaid Services, 254–255
Healthy People 2010, 253–254
governmental quality outcome initiatives and, 253–257
not-for-profit organization initiatives, 257–258
Foundation for Accountability, 257–258
professional society initiatives, 258–259
state government initiatives, 255–256
in error measurement and reporting, 376–378
management of, 377, 381
capture of process and structure errors in, 377–378, 381
untoward intermediate outcome and, 377

Outcomes manager, for mechanical ventilation on medical ICU, daily routine of, 236–237
goals of, 236
monitoring, managing, reporting of outcomes, 237–239
role of, 236
obstacles to, 237, 240
selection of, 233

Outcomes research, historical perspective on, 293
in advanced practice nursing, common health care outcomes in, 262
comparison of advanced practice nurse with other healthcare providers in, 272
conceptual frameworks for, dynamic reciprocal relationships, 264
interrelationship of structure and process, 263–264
structure-process-outcome, 263
databases for, administrative, 265–267
clinical, 267
data sources for, 247, 249
definition of, 261–262
evolution of, 261–262
funding agency and award, 249
impact of advanced practice nursing care in, 272
interpretation of results and, 271–272
measuring impact of advanced practice nurse, 269, 272–273
outcome indicators in, 249
overview of past decade, 245–246
professional preparation for, 247
data sources and data management, 249
funding agency and award, 248
outcome indicators, 248–249
scope of study, 248
study design, 248
published literature, 269, 271
organization of studies and, 271
research team for, 249–250
risk adjustment in, controlling for, 264–265
for age, 264
for case mix, 264–265
for DRGs, 264
for gender, 264
for race/ethnicity, 264
for severity of disease, 265
for severity of illness, 265
scope and intent of study, 248
skills needed for, 246–247
data sources, 247
outcome indicators in, 247
scope and intent of study and, 247
study design for, 246
specialty areas addressed in, 270–271
study design in, 246, 248
team composition for, 249–250
tracking outcomes in, 272
vs. clinical research, 261–262

Outcomes research design, for advanced practice nursing outcomes
analysis of results in, 295–297
comparison of groups in, 296
description of, 295–296
risk adjustment and statistical control of covariates, 296–297
time to event in, 297
design for future research, 297
design selection in, 293–294, 296–297
measurement in, 294–295
problem identification for, 293
question development for, 293

Over-the-counter drugs, use by elderly, 115, 117

Oxazolidine, for gram-positive infections, 24–25

P

Pain, in elderly, medication for, 117–118

Pain management, ethical distress *vs.* ethical dilemma and, 167
ethical principles in, 166–167
ethical violations in, paternalism *vs.* autonomy, 167–168
ineffective, at end of life, 165–166
in end of life care, 146
case example of, 165–166
ethical issues in, **165–170**
ethical principles in, 166–167
ethical violations in, 167–168
ethics committee consult in, 169
standards of care and, 168
rule of double effect in, 146

Palliative care
advance practice nurses and, 130
ancillary support services and, 131
barriers to, 142–143
definitions of, 128, 208
disintegration in ICU staff and processes and, 137–138
emergence of, **127–132**
holistic approach to, 138–139
hospice and, 128
hospital based, 130
integration of "doing" and "being" in, 139
integration with critical care, **133–140**
interdisciplinary approach in, 130–131
medical specialist consultants in, 131
nurses and, 130–131
pediatric, barriers to, 208
description of, 208
family-centered model of, **207–214**
needs in, 210–211
research in, 212
services for, 211–212
physicians and, 130
precepts for best practice, 137–138
precepts of, 202
relationships in, 138–139
Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatment and, 127
traditional medication training *vs.*, 127–128
withdrawal of nutritional support in, 194–195

Pancreas, in elderly, insulin uptake and, 431

Partnership in health care, for risk management, advocates 24 hours/day, 7 days/week, 394
aviation model and, 393
obstacles to, adversarial system, 392
appointment time limit, 392
communication deficit, patient's, 392
physician's, 392
economics of reimbursement, 395
fear, 392–393
intimidation by system, 393
one-way communication, 392
patient's story, **391–399**
changing physicians and, 398
obstacles to, 392–396
physicians in, 392–396
physicians in, impatience of, 396
participation in partnering, 394–395
respect from, 394
system/team failure, in test results communication, 397–398
system *vs.* individual failure in, 395–396
teamwork model for, **333–340**

Paternalism, in ICU care, 158–159
vs. beneficence, in pain management at end of life, 166–167

Patient education, in advance directives, **215–217**

Patient safety, engaging nurses in, **341–346**
in Memorial Hermann Hospital/Memorial Hermann Children's Hospital, **341–346**
culture and teamwork in, 342–343
medication ordering and administration, 341–343
nurse-identified issues in, 343–345
education, 344–345
staff levels, 344
standardization of equipment and protocols, 344
team input in decision-making, 344
system evaluation in, for hindering system factors, 354
for supporting system factors, 354
for sustainability of change, 354–355
for weak human factors, 353–354
weak human factors in, 353–354
systems approach to, 341–342
Institute of Medicine and, 348
issues in, nurse-identified, 343–345
JCAHCO standards for, 347
Leapfrog group and, 347–348
medication administration safety in, 341–342
teamwork model of, **333–340**

Patient Self-Determination Act (PSDA), and end of life decisions, 187

Peaceful death, American Association of Colleges of Nursing on, competencies for, 201–202
caregiver concerns in, acknowledging and addressing, 204
comprehensive caring in, 203–204
interdisciplinary resources in, 204
respect for patient goals, preferences, choices and, 202–203
support of, systems and mechanisms for, 204–205

Pediatric acute care. See also *Acute care.*
advanced practice nurse in, **313–324**
historical perspective, 314
issues in, consistency in educational preparation, 316–317
integration into unit leadership, 320
recognition of practice, 318–319
reimbursement for services, 319–320
role definition, 317–318
supervision, scheduling, staffing, 320
support for continuing education, 321
literature review of, role in, 314–315
clinical nurse specialist in, 313–314
role of, 315
in neonatal ICU, clinical nurse specialist and nurse practitioner in, 315
in pediatric ICU, pediatric critical care nurse practitioner in, 316
pediatric nurse practitioners in, 316
nurse practitioner in, 313–315

Pediatric critical care nurse practitioner (PCCNP), in pediatric ICU, 316

Pediatric intensive care unit, ethical issues in, 160

Pediatric nurse practitioner (PNP), collaboration with physician, 308–309
on pediatric ICU, 316

Penicillins, for gram-positive infections, 21–22

Pharmacist, in error prevention, 351

Pharmacodynamics, defined, in elderly, 111–113

Pharmacokinetics, defined, in elderly, 111–112

Phenylephrine, for decreased afterload, 75

Phenytoin, parenteral, for seizure control, limitations of, 31

Phosphate, serum, in diabetes mellitus, 90

Physician, advance directives and, 215–216
advanced practice nurse relationship with, 302, 304
education of, for end of life care, 217
for pediatric palliative care, 211
in advanced practice–physician practice, 226–227, 279, 306–310. See also *Collaborative practice.*
in error prevention, 350
in partnership in health care, 394–396
palliative care and, 130, 211
withdrawal of life support and, 187–188

Pneumonia, nosocomial, endotracheal tube-associated, 420
gastrointestinal tract in, 420
risk reduction strategies for, 419–420
ventilator-associated, 419–420

Politics, in multisite advanced practice nursing, 302–303

Potassium, serum, in diabetes mellitus, 90

Practice models, for advanced practice nursing, 223–224
collaborative/joint, 226–227
group, 227–228
hospital, 228
private, 224–226
for healthcare, 223

Prayer, and end of life care, 174

Private practice, in advanced practice nursing, business aspects of, 225
challenges and rewards of, 225
criteria for success, 225
independent practice, 224
lifestyle considerations in, 225–226
roles and responsibilities in, 225

Procainamide, indications and action of, 54–55

Propafenone, indications and action of, 59

Propofol, contraindications to, 36
dosing of, 35
hypotension with, 36
infection prophylaxis with, 36–37
in neuroscience intensive care unit, for sedation, 35–37
pharmacokinetics of, 35–36
respiratory depression with, 36
seizures with lightening of, 37
weaning from, 37–38

Propranolol, adverse effects of, 60
indications and action of, 59

Prostaglandin analogues, for stress ulcers, 48

Protocols, standardization of, for patient safety, 344

Proton pump inhibitors, for stress ulcers, 47–48

Pulmonary function, in elderly, inhalant medication administration safety and, 430

Pulmonary hypertension, in newborn. See *Pulmonary hypertension of the newborn (PPHN).*

Pulmonary hypertension of the newborn (PPHN), causes of, 1
classification of, 1–2
inhaled nitric oxide for, 2–3
treatments for, extracorporeal membrane oxygenation, 2
hyperventilation, 2
pharmacologic, 2

Pyridoxine, for stress ulcers, 49

Q

Quality in health care, as public mandate, 375–376
definition of, 376
measurement and reporting of, goals in, 375
need for, 376

Quality of care, in advanced practice nursing, 277–278

Quality of life, of aging patients, physical functioning in, 284–285

Quinidine, indications and action of, 55

Quinolones, for gram-positive infections, 25–26

Quinupristin, for gram-positive infections, 23–24

R

Race, advance directives and, 215

Race/ethnicity, in outcomes research, controlling for, 264

Rate control, pharmacotherapy for, 66

Refusal of treatment, in critical care, 145
in intensive care unit, 162

Reimbursement, of advanced practice nurse, in pediatric acute care, 319–320

Renal failure, drug use in, **77–80**
absorption of, 77, 79
bioavailability and, 77
distribution and, 77–79
dosimetry in, 78
drug monitoring and, 79
excretion and, 78–79
initial dose in, 79
pharmacokinetics and, 78
protein binding and, 78–79
renal function estimation for, 78–79
research issues in, current, 79

Research, end of life care and, 150

Resources, for continuity, access, communication, in multisite advanced practice nursing, 303

Respect for persons, in ICU care, 159

Respiratory therapist, in error prevention, 351

Restraints, in ICU, 161

Resuscitation, family presence during, **177–185**
benefits of, 182
Emergency Nurses Association document and, 178–179, 183
Foote Memorial Hospital program and, 177–178
future issues in, 183–184
health care providers' perspective on, 178–180, 182–183
institutional implementation of, 183
need for *vs.* fear of, 182
Parkland Health and Hospital System and, program implementation for, 179–180
patient's perspective and, 181
in end of life care, 147
sanctity of life *vs.* quality of life and, 147

Rifampin, 26

Risk reduction, for nosocomial infections, 419–422
in patient care setting, multidisciplinary, **359–367**

Root cause analysis, in error reduction, 360, 363–365
limitation of, 385
of medication errors, 374

S

Safety. See also *Patient safety.*
aviation model of, adaptation to health care, 334–335
in health care delivery, 333–334
violations of, comparison of aviation and health care, 334

Safety culture, development of, critical thinking in, 388–390
novice-to-expert pathway in, 389–390

Satisfaction, patient/family/physician, with advanced practice nursing, 277

Sedation, in neuroscience intensive care unit, haloperidol for, 37
midazolam for, 37
propofol for, 35–37

See also *High-alert medication*

Seizures, with propofol use, 37

Self-determination, and end of life decisions, 187
withdrawal of nutritional support and, 193

Self-evaluation, in multisite advanced practice nursing, 300

Sentinel event, JCAHCO definition, 414

Severity of disease, in outcomes research, controlling for, 265

Severity of illness, in outcomes research, controlling for, 265

Shock trauma intensive care unit (STICU), at Memorial Hermann Hospital, changes in, for patient safety, 344–345

Similarity matching, errors and, 386

Sinus rhythm, maintenance of, pharmacotherapy for, 67

Sirolimus, for immunosuppression, 105

Skill, *vs.* knowledge, in patient safety, 352–353

Slips, as errors routines, 386

Sodium, serum, in diabetes mellitus, 90

Sotalol, adverse effects of, 61–62
indications and action of, 62

Spiritual care, at end of life, **171–176**
and spiritual integration, 172
caregiver tasks and needs in, 175–176
description of, 171–172
family tasks and needs in, 173–175
illustration of, 171
improvement of, 176
nurse's role in, 172–173
spirituality and, 172

Spirituality, family presence during resuscitation and, 184

Spiritual needs, in end of life care, caregiver, 175–176
children, 211
family, 173–175, 211

Staffing, nosocomial infections and, prevention of, 418

Staff levels, increase in, for patient safety, 344

State government initiatives, outcome selection from, for advanced practice nursing research, 255–256

Status epilepticus, fosphenytoin for, 32

Stress ulcers, Curling's, 40, 42
Cushing's, 40, 42
description of, 40, 42
diagnosis of, endoscopy in, 45
hematest of occult blood in, 44
pH of nasogastric aspirate in, 44–45
manifestations of, 44
pathogenesis of, hypersecretion of acid and gastrin in, 41
intraluminal acid, pepsin, bile salts, urea in, 40–41
ischemia in, 41–42
physiologic stress response in, 41
pathology of, cortisol increase in, 44
gastric mucosa impairment in, 44
ischemia of gastric mucosa in, 42–44
pathophysiology of, 41–42
gastric physiology in, normal, 41–42
mucosal barrier in, 41
mucosal blood flow and epithelial cell regeneration in, 42
mucus secretion in, 41–42
pathophysiology of prostaglandins in, 42
pharmacologic prophylaxis and treatment of, **39–51**
antacids in, 45–46
critical care clinician in, 49
histamine-2-receptor antagonists in, 46–47
magnesium in, 49
new, 48
nutrition in, 48
prostaglandin analogues in, 48
proton pump inhibitors in, 47–48
pyridoxine in, 49
sucralfate in, 46
vitamin E-selenium combination in, 48–49
risk factors for, 39–40

Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatment (SUPPORT), lessons learned from, 128–129
palliative care and, 127
programs following, 129–130

Substituted judgment, surrogate decision making and, 144

Sucralfate, for stress ulcers, 46

Suicide, assisted, 148

Surrogate decision making, in end of life care, 144
in ICU care, 161

Systems, in patient safety, 341–342

T

Tacrolimus, for immunosuppression, 104, 107

Taste, in elderly, medication administration safety and, 429

Teamwork model, for patient safety, **333–340**
as significant variable, 334
behavior model of, 335–336
collaborative *vs.* hierarchical relationships in, 337–338
organizational climate and, 336
partnerships in, cornerstones of, 338–339
personal skills in, 338–339
relational model in, 337–338
relationship-centered care and, 336–337

Telithromycin, for gram-positive infections, 23

Thienopyridines, as platelet receptor antagonists, 11–12

Thrombin inhibitors, in anticoagulation, 14

Ticlopidine, as platelet receptor antagonist, 11

Tirofiban, in anticoagulation, 12

Tissue plasminogen activator (t-PA), bleeding with, 35
contraindications to use, 34
for acute myocardial infarction, in elderly, 118
for stroke *vs.* for acute myocardial infarction, 33–34
in elderly, 118

Touch, in elderly, medication administration safety and, 429

Tromethamine, for acidemia, systemic, 76

U

Untoward intermediate outcome (UIO), identification of, 377
in error identification, 377

Urea nitrogen, serum, in diabetes mellitus, 90

Urinary tract infection, nosocomial, Foley catheter-associated, 419
risk reduction strategies for, 419

Utilitarian (consequentialist) ethics, error reporting and disclosure in, 403–404

V

Valproate, parenteral formulation of, 33

Values, in end of life care, 135–136

Vancomycin, for gram-positive organisms, 23

Vasoconstrictors, with fluid resuscitation, 74

Vasodilation, for high afterload, 75

Vasopressors, for decreased afterload, 75

Verapamil, adverse effects of, 64
indications and action of, 664–65

Vision, in elderly, medication administration safety and, 429

Visiting hours, and end of life care, 174–175

Vitamin E-selenium combination therapy, for stress ulcers, 48–49

Volunteers, education of, for pediatric palliative care, 211–212

W

Warfarin, history of, 7

Weaning protocol, from mechanical ventilation on medical ICU, in advanced practice nursing program, 232, 237–240

Weight loss, drug-induced, in elderly, 115–116

White blood count, in diabetes mellitus, 91

Withdrawal of hydration, in end of life care, benefits from, 145–146, 195

Withdrawal of life support, advance directives and, 190
communication in, 188–190
environment in, 190–191
literature review of, advance directives and, 187–188
family needs during, 187–189
nurses and, 187–188
physicians and, 187–188
studies of, 189–191

Withdrawal of nutritional support, advance directives and, 194
benefit *vs.* burden ratio in, 195
in end of life care, 145–146
legal and ethical considerations in, 193–194
myths concerning, 194

palliative care and, 194–195
recommendations for, 195–196
self-determination and, 193

Withdrawal of ventilatory support, for dying patient, 203–204

Withholding treatment, in end of life care, 145

Wound(s), nonsurgical, nosocomial infection of, debridement of, 422
dressing of, 422
surgical site, nosocomial infections in, 422–423
reduction strategies for, 423
risk factors for, 423
microbe-related, 423